BioSpace News Archive

Gensaic, a company that seeks to reimagine gene therapy, announced that it has received an investment from the CF Foundation to develop a gene therapy for Cystic Fibrosis.

Sengenics Corporation LLC, driving the discovery of next-gen biomarkers through its immuno-proteomic platform, KREX®, and Summa Equity announce that Yvonne Linney PhD. has been appointed to the company’s Board of Directors, effective immediately.

SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced that David Lowndes will be appointed as Chief Operating Officer.

OncoPep, Inc. is proud to be a presenter at this year’s Biotech Showcase January 9-11 in San Francisco.

Revive Therapeutics Ltd. announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC and interim safety data from exploratory cohort C, a cohort of 15 patients with advanced ovarian cancer treated at the higher dose of luvelta, (5.2mg/kg), along with prophylactic pegfilgrastim.

NeuroPace, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors.

Assertio Holdings, Inc. announced that U.S. Patent, No. 11541002 for Sympazan® oral film is now listed in the U.S. Food and Drug Administration publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

CONMED Corporation announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, February 2, 2023.

Solid Biosciences Inc., a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan.